Mechanical ventilation

Active Ingredient: Cisatracurium

Indication for Cisatracurium

Population group: only infants (40 days - 1 year old) , children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Cisatracurium can be used as an adjunct to general anaesthesia, or sedation in the Intensive Care Unit (ICU) to relax skeletal muscles, and to facilitate tracheal intubation and mechanical ventilation.

For this indication, competent medicine agencies globally authorize below treatments:

0.03 to 0.6 mg/kg/hr

For:

Dosage regimens

Intravenous, between 0.03 milligrams cisatracurium per kilogram of body weight and 0.6 milligrams cisatracurium per kilogram of body weight, hourly.

Detailed description

Dosage in Intensive Care Unit (ICU) patients

Cisatracurium may be administered by bolus dose and/or infusion to adult patients in the ICU.

An initial infusion rate of cisatracurium of 3 ฮผg/kg (body weight)/min (0.18 mg/kg/hr) is recommended for adult ICU patients. There may be wide interpatient variation in dosage requirements and these may increase or decrease with time. In clinical studies the average infusion rate was 3 ฮผg/kg/min [range 0.5 to 10.2 ฮผg/kg (body weight)/min (0.03 to 0.6mg/kg/hr )].

Table 6 provides guidelines for delivery of undiluted cisatracurium Forte (5mg/ml) injection.

The median time to full spontaneous recovery following long-term (up to 6 days) infusion of cisatracurium in ICU patients was approximately 50 minutes.

Table 6. Infusion Delivery Rate of cisatracurium Forte injection 5 mg/ml:

Patient (body weight) (kg)Dose (ยตg/kg/min)Infusion Rate
1.01.52.03.0
700.81.21.72.5mL/hr
1001.21.82.43.6mL/hr

The recovery profile after infusions of cisatracurium to ICU patients is independent of duration of infusion.

Active ingredient

Cisatracurium

Cisatracurium is an intermediate-duration, non-depolarising benzylisoquinolinium skeletal muscle relaxant. Cisatracurium binds to cholinergic receptors on the motor end-plate to antagonise the action of acetylcholine, resulting in a competitive block of neuromuscular transmission. This action is readily reversed by anti-cholinesterase agents such as neostigmine or edrophonium.

Read more about Cisatracurium

Related medicines

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.